mRNA-Based Gene Editing Therapy Shows Promise for Untreatable Cystic Fibrosis Mutation

April. 30, 2026-

A research team led by the University of Trento has unveiled a promising mRNA-based gene editing therapy targeting a subset of Cystic Fibrosis patients who currently have no effective treatment options. The findings, published in Science Translational Medicine, could mark a meaningful step toward a durable or potentially curative approach for the disease.

Cystic fibrosis affects more than 100,000 people worldwide and is driven by mutations in the CFTR gene, which encodes a protein essential for regulating ion transport, mucus hydration, and lung function. While existing therapies have improved outcomes for many patients, approximately 10% of individuals carry mutations that do not respond to current drugs.

The new study focuses on one such mutation—1717-1G>A—and introduces a precision gene editing strategy delivered via mRNA. Rather than adding a functional copy of a gene (as seen in many Adeno-associated virus (AAV)-based gene therapies), this approach directly repairs the defective DNA sequence at its source.

Led by Anna Cereseto, the research team developed a system capable of editing a single nucleotide—replacing a disease-causing adenine with guanine—thereby restoring the correct genetic instructions needed to produce functional CFTR protein.

This editing machinery is delivered transiently via messenger RNA, allowing the correction to occur without permanently introducing foreign genetic material into the body. Once the edit is made, the mRNA degrades naturally, reducing long-term safety concerns often associated with sustained gene-editing activity.

Preclinical validation was conducted in collaboration with the Telethon Institute of Genetics and Medicine and KU Leuven, using lung epithelial cells and patient-derived intestinal organoids. These models demonstrated functional restoration of CFTR activity, supporting the therapeutic potential of the approach.

While the results are encouraging, a major challenge remains: efficient delivery to lung tissue. The research team is now focusing on developing delivery systems—potentially including inhalable formulations—that can transport the mRNA-based editor directly to airway epithelial cells.

This work highlights a broader shift in the gene therapy field toward precision editing and non-viral delivery approaches, complementing established AAV-based strategies. If successfully translated into the clinic, such technologies could expand treatment access to patient populations historically left behind by conventional therapies.